Description

(2S,3S)-n-[(2-Amino-4-Thiazolyl)[(Z)-[(Sodiooxycarbonyl)Methoxy]Imino]Acetyl]-3-[(Sodiooxysulfonyl)Amino]-o-Carbamoylhomoserine Sodium Salt is a sophisticated, high-purity chemical intermediate belonging to the class of advanced β-lactamase inhibitors. This compound is critical for the synthesis of next-generation antibiotic formulations, offering enhanced stability and efficacy. It is primarily required by pharmaceutical R&D laboratories and manufacturers specializing in potentiated penicillin and cephalosporin antibiotics to combat resistant bacterial strains.

Application

• Pharmaceutical Intermediate: Key building block in the synthesis of advanced β-lactamase inhibitors like tazobactam and related analogs.
• Antibiotic Potentiation: Used in combination drug development to restore the efficacy of β-lactam antibiotics against resistant bacteria.
• Research & Development: Essential for medicinal chemistry research focused on novel antimicrobial agents and resistance mechanisms.
• Active Pharmaceutical Ingredient (API) Synthesis: Intermediate in the multi-step production of finished drug substances for injectable formulations.
• Process Chemistry: Serves as a critical chiral synthon in scalable GMP manufacturing processes for regulated markets.

Basic Information

Product Name	(2S,3S)-n-[(2-Amino-4-Thiazolyl)[(Z)-[(Sodiooxycarbonyl)Methoxy]Imino]Acetyl]-3-[(Sodiooxysulfonyl)Amino]-o-Carbamoylhomoserine Sodium Salt
CAS No.	103618-99-1
Molecular Formula	C14H16N6Na2O10S2
Molecular Weight	554.41 g/mol
Synonyms	(2S,3S)-3-[[(Aminosulfonyl)oxy]amino]-2-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[[(1-carboxy-1-methoxy)imino]acetyl]amino]-4-carbamoylbutanoic acid disodium salt; Tazobactam Intermediate; Tazobactam Disodium Salt Derivative; (2S,3S)-3-[(Sulfonyloxy)amino]-2-[(Z)-2-(2-aminothiazol-4-yl)-2-[(1-carboxy-1-methoxy)imino]acetamido]-4-carbamoylbutanoic acid disodium salt; Penicillanic acid sulfone derivative; YTR 830H Intermediate; CL 298741 Intermediate
EINECS	Contact for details

Quality Control

Our production of this advanced intermediate adheres to stringent pharmaceutical-grade standards. Every batch is subjected to comprehensive analytical testing, including chiral purity verification and impurity profiling via HPLC, to ensure it meets the exacting requirements for API synthesis. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting identity, assay, and related substances. We support compliance with cGMP, ICH Q7, and relevant pharmacopoeial guidelines for intermediates.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive) and must be kept under dry, inert conditions to maintain stability and potency. For long-term storage, consider desiccated or nitrogen-purged environments.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0% (anhydrous basis)
Chiral Purity (HPLC)	≥ 99.0% (2S,3S isomer)
Water Content (KF)	≤ 2.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 0.5%
Residual Solvents (GC)	Complies with ICH Q3C

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.